pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·2h ago·1 min read
save

ADA faces member backlash and calls for CEO and CSO resignations after expert expulsions

Jul 28, 2026·read at STAT ↗Negative

The American Diabetes Association’s 2026 Scientific Sessions in New Orleans ended with the expulsion of five diabetes experts, sparking a wave of criticism.

More than 200 members signed an open letter demanding the removal of CEO Charles Henderson and chief scientific and medical officer Rita Kalyani. The letter also asks for an independent investigation, a formal apology to the expelled colleagues, and restored editorial independence for the journal Diabetes Care.

In response, the ADA thanked members for their patience while it prepares a report, but it has not taken any decisive action despite the incident occurring over 45 days ago.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: American Diabetes Association, facing calls for resignations, asks for patience”

read at STAT ↗
549 words · retrieved 2h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 6h agoSix key issues we’re watching at Fauci’s hearingSTAT
  • 9h agoVisa time limits on foreign Ph.D. students and postdocs will harm U.S. science, experts warnSTAT
  • 9h agoSTAT+: Bracing for another Fauci hearingSTAT
  • 11h agoSTAT+: GSK lays out plans to cut costs, pursue more late-stage drug trialsSTAT
  • 12h agoSTAT+: FDA staff reiterate concerns about Replimune skin cancer treatmentSTAT